<DOC>
	<DOCNO>NCT02737475</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , pharmacodynamics preliminary anti tumor activity BMS-986178 administer alone combination Nivolumab Ipilimumab subject advance solid tumor .</brief_summary>
	<brief_title>Study BMS-986178 Monotherapy Combination With Nivolumab Ipilimumab Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Patients must least 1 standard treatment regimen advance , recurrent metastatic setting ECOG ( Eastern Cooperative Oncology Group ) 01 Men woman 18 year old old At least one measurable lesion baseline CT ( compute tomography ) MRI ( magnetic resonance imaging ) per RECIST ( Response Evaluation Criteria In Solid Tumors ) v1.1 Known central nervous system metastases central nervous system source disease Concomitant malignancies Active know suspect autoimmune disease Uncontrolled significant cardiovascular disease Major surgery less 4 week start study Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>